EP2032139A4 - COMPOSITIONS USING NANOTEHOUS MELOXICAM AND HYDROCODON WITH CONTROLLED RELEASE - Google Patents

COMPOSITIONS USING NANOTEHOUS MELOXICAM AND HYDROCODON WITH CONTROLLED RELEASE

Info

Publication number
EP2032139A4
EP2032139A4 EP07784540A EP07784540A EP2032139A4 EP 2032139 A4 EP2032139 A4 EP 2032139A4 EP 07784540 A EP07784540 A EP 07784540A EP 07784540 A EP07784540 A EP 07784540A EP 2032139 A4 EP2032139 A4 EP 2032139A4
Authority
EP
European Patent Office
Prior art keywords
compositions
controlled release
release hydrocodone
nanoparticulate meloxicam
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07784540A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2032139A2 (en
Inventor
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Eugene R Cooper
Tuula Ryde
John Pruitt
Laura Kline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of EP2032139A2 publication Critical patent/EP2032139A2/en
Publication of EP2032139A4 publication Critical patent/EP2032139A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07784540A 2006-06-23 2007-06-25 COMPOSITIONS USING NANOTEHOUS MELOXICAM AND HYDROCODON WITH CONTROLLED RELEASE Withdrawn EP2032139A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588406P 2006-06-23 2006-06-23
PCT/US2007/072054 WO2007150075A2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone

Publications (2)

Publication Number Publication Date
EP2032139A2 EP2032139A2 (en) 2009-03-11
EP2032139A4 true EP2032139A4 (en) 2012-08-22

Family

ID=38834447

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07784540A Withdrawn EP2032139A4 (en) 2006-06-23 2007-06-25 COMPOSITIONS USING NANOTEHOUS MELOXICAM AND HYDROCODON WITH CONTROLLED RELEASE

Country Status (11)

Country Link
EP (1) EP2032139A4 (no)
JP (1) JP2009541360A (no)
KR (1) KR20090023729A (no)
CN (1) CN101484169A (no)
AU (1) AU2007260822B2 (no)
CA (1) CA2660650A1 (no)
IL (1) IL196066A0 (no)
MX (1) MX2008016115A (no)
NO (1) NO20090119L (no)
WO (1) WO2007150075A2 (no)
ZA (1) ZA200810098B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CA2763456C (en) * 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CN103070906A (zh) * 2011-12-08 2013-05-01 赵联华 一种治疗骨科疾病的注射用组合物的质量控制方法
MX354579B (es) * 2011-12-29 2018-03-12 Laboratorios Andromaco S A Ex Inversiones Gruchi S A Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2021257784A1 (en) * 2020-06-18 2021-12-23 Verté Therapeutics, Llc Injectable meloxicam formulations
CN113181249B (zh) * 2021-05-25 2022-06-14 重庆市畜牧科学院 一种抗仔猪腹泻的中药缓释颗粒的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013799A1 (en) * 1997-09-17 1999-03-25 Euro-Celtique, S.A. Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
WO2001032148A1 (en) * 1999-10-29 2001-05-10 Euro-Celtique, S.A. Controlled release hydrocodone formulations
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070051953A (ko) * 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013799A1 (en) * 1997-09-17 1999-03-25 Euro-Celtique, S.A. Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
WO2001032148A1 (en) * 1999-10-29 2001-05-10 Euro-Celtique, S.A. Controlled release hydrocodone formulations
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release

Also Published As

Publication number Publication date
WO2007150075A3 (en) 2008-04-24
KR20090023729A (ko) 2009-03-05
EP2032139A2 (en) 2009-03-11
CA2660650A1 (en) 2007-12-27
MX2008016115A (es) 2009-01-20
NO20090119L (no) 2009-03-20
ZA200810098B (en) 2009-12-30
CN101484169A (zh) 2009-07-15
JP2009541360A (ja) 2009-11-26
WO2007150075A2 (en) 2007-12-27
IL196066A0 (en) 2009-09-01
AU2007260822B2 (en) 2012-07-05
AU2007260822A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
IL196066A0 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
IL184174A0 (en) Nanoparticulate and controlled release compositions comprising cephalosporin
IL244442B (en) Compounds of converted acylanilides and their use
IL195524A0 (en) Nanoparticulate posaconazole formulations
ZA200810221B (en) Compositions comprising nanopaticulate naproxen and controlled release hydrocodone
IL199006A0 (en) Nanoparticulate formulations and methods for the making and use thereof
EP2074142A4 (en) COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
ZA200807397B (en) Nanoparticulate carvedilol formulations
GB0621160D0 (en) Compounds and uses thereof
EP2077863A4 (en) intrabodies
IL187431A0 (en) Nanoparticulate and controlled release compositions comprising a cephalosporin
GB0611115D0 (en) Compounds and their use
EP2124908A4 (en) CONNECTIONS AND ITS USE
HK1117060A1 (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP1977992A4 (en) NANOSEMICONDUCTOR PARTICLE
TWI348269B (en) Transceiver and compound fileter
EP2120563A4 (en) CONNECTIONS AND ITS USES
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
ZA200701372B (en) Loading device
TWI370812B (en) Ester compound and its use
EP2016388A4 (en) PARTICLE MONITORING DEVICE
GB0614871D0 (en) Proximity activated camera
GB0619611D0 (en) Compounds and their use
ZA200710715B (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
IL197074A0 (en) Thiadiazole compound and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KLINE, LAURA

Inventor name: PRUITT, JOHN

Inventor name: RYDE, TUULA

Inventor name: COOPER, EUGENE R.

Inventor name: SINGH-REKHI, GURVINDER

Inventor name: JENKINS, SCOTT

Inventor name: LIVERSIDGE, GARY

Inventor name: FANNING, NIALL

Inventor name: DEVANE, JOHN

Inventor name: STARK, PAUL

A4 Supplementary search report drawn up and despatched

Effective date: 20120723

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101ALI20120717BHEP

Ipc: A61K 9/14 20060101ALI20120717BHEP

Ipc: A61K 9/51 20060101ALI20120717BHEP

Ipc: A61K 31/485 20060101AFI20120717BHEP

Ipc: B32B 25/00 20060101ALI20120717BHEP

Ipc: A61K 9/54 20060101ALI20120717BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130103